Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. is a biotechnology company founded in 2006, with its headquarters in the United States. The company is focused on genetic engineering research for the development and commercialization of spider silks. Their breakthrough in developing a practical and cost-effective technology for producing recombinant spider silk-based fibers on an industrial scale has positioned the company as a leader in the industry. Their last investment of $8.00M in post-IPO equity was made on 21 November 2022 by Yorkville Advisors. Kraig Biocraft Laboratories is committed to pioneering the next generation of high-performance fibers and is enthusiastic about the potential impact of their spider silk technology on the global textiles industry. With a focus on product development and innovative solutions, the company's advancements in genetic research hold promise for a wide range of consumer and industrial applications in the textiles and performance polymers market. As a fully reporting company, their annual and quarterly reports to the SEC can be found on EDGAR, offering transparency and compliance. Their dedication to research, development, and commercialization positions them as a potential contender for strategic investment opportunities in the biotechnology sector.